VativoRx, LLC

03/13/2026

🩸 FDA expands Darzalex Faspro® use.

The therapy is now approved with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for stem cell transplant. Studies have shown improved treatment response and a lower risk of disease progression.

https://vativorx.com/pharmacy-bulletin-03-13

On March 10, 2023, the U.S. Food and Drug Administration (FDA) approved Daybue™ (trofinetide) oral solution. It is the first drug indicated to treat the underlying cause of Rett syndrome for patients at least two years old.

03/10/2026

For years, PBM transparency has been a policy debate.
It may now be becoming a fiduciary responsibility.

The Consolidated Appropriations Act of 2026 and new Department of Labor rulemaking suggest pharmacy benefit economics may be moving closer to the formal governance workflow of group health plans.

In this edition of The Rebate Report, we look at why rebate transparency may be shifting from a contractual discussion to an operational responsibility for plan sponsors, TPAs, and advisors.

https://www.linkedin.com/pulse/rebate-transparency-moving-plan-file-vativorx-llc-svyue

03/02/2026

FDA update: Nexplanon® is now approved to prevent pregnancy for up to 5 years (previously 3). ✅ One small implant in the upper arm, placed by a trained provider. The FDA also added a new safety/training program for insertion & removal.

https://vativorx.com/pharmacy-bulletin-03-02-2026/

On Jan. 16, 2026, the US Food and Drug Administration (FDA) extended the duration of use for Nexplanon® (etonogestrel implant - Organon) 68mg radiopaque, from three to five years for the prevention of pregnancy in women of reproductive potential. Nexplanon is a long‑acting, reversible, progestin....

02/20/2026

CMS is emphasizing payment accuracy in Medicare Advantage — and even modest policy shifts can change provider realities fast.

Edition 22 of The Rebate Report covers what’s changing and the key watchpoints for hospitals, outpatient facilities, and infusion centers: UM friction, contracting posture, and documentation sensitivity.

https://www.linkedin.com/pulse/medicare-advantage-whats-changing-what-watch-vativorx-llc-foiae

CMS has signaled a sharper emphasis on payment accuracy in Medicare Advantage (MA), and while the headlines often focus on plan payments, the downstream impact matters most for provider organizations. In the CY 2027 Medicare Advantage and Part D Advance Notice, CMS projects a net average year-over-y

02/19/2026

Nexplanon® Now Approved for 5 Years

The FDA extended Nexplanon’s duration of use from 3 to 5 years for pregnancy prevention.

The long-acting implant showed no pregnancies in years 4–5 of clinical trials, with no new safety concerns.

A new REMS program will enhance provider training for safe insertion and removal.

https://vativorx.com/pharmacy-bulletin-02-19-2026/

On Jan. 16, 2026, the US Food and Drug Administration (FDA) extended the duration of use for Nexplanon® (etonogestrel implant - Organon) 68mg radiopaque, from three to five years for the prevention of pregnancy in women of reproductive potential.

02/18/2026

The Health Care Administrators Association® (HCAA) Executive Forum is coming up next week, and we’re looking forward to thoughtful, practical conversations with industry leaders focused on transparency, compliance, and sustainable cost strategies across healthcare.

02/13/2026

As healthcare costs continue to rise, organizations are re-evaluating how they approach specialty drug spend, medical benefits, and compliance.

Events like the HCAA Executive Forum create space for practical, experience-driven conversations around what’s working and what’s next.

02/12/2026

Cerezyme® Label Expanded for Gaucher Disease

The FDA expanded approval of Cerezyme® to include Type 3 Gaucher disease and children under 2 years old for non-CNS symptoms.

This broadens access and allows earlier treatment in pediatric patients.

https://vativorx.com/pharmacy-bulletin-02-12-2026/

On Jan. 12, 2026, the FDA approved an indication expansion for Cerezyme® (imiglucerase – Genzyme Corporation), extending its use to treat non–central nervous system (CNS) manifestations of Type 1 and Type 3 Gaucher disease in adult and pediatric patients, including newly expanded eligibilit...

02/11/2026

TrumpRx is trending, but the bigger story is what it signals: pricing expectations are moving closer to the point of care.

Edition 21 breaks down what’s known so far and the three operational watchpoints provider organizations should track.

https://www.linkedin.com/pulse/trumprx-what-watch-vativorx-llc-cqvie

02/05/2026

Industry conversations continue to shift toward compliance, transparency, and accountability in healthcare cost management.

These themes are becoming central to how organizations think about sustainability and long-term value, and they’ll be front and center at this year’s HCAA Executive Forum.

02/04/2026

🆕 FDA approval: Lunsumio Velo™ is now available as a 1-minute under-the-skin injection for adults with relapsed/refractory follicular lymphoma after 2+ prior treatments. Same cancer-fighting power, way less chair time.

https://vativorx.com/pharmacy-bulletin-02-04-2026/

On Jan. 5, 2026, the US Food and Drug Administration (FDA) approved Sanofi’s Cablivi® (caplacizumab-yhdp) for injection to treat pediatric patients 12 years and older who have acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy.